bioMérieux S.A. (BMXXY)
- Previous Close
12.95 - Open
11.42 - Bid 13.44 x 20000
- Ask 14.08 x 10000
- Day's Range
11.42 - 11.42 - 52 Week Range
9.51 - 12.95 - Volume
6 - Avg. Volume
417 - Market Cap (intraday)
14.531B - Beta (5Y Monthly) 0.48
- PE Ratio (TTM)
27.19 - EPS (TTM)
0.42 - Earnings Date Sep 4, 2025
- Forward Dividend & Yield 0.10 (0.76%)
- Ex-Dividend Date Jun 10, 2025
- 1y Target Est
--
bioMérieux S.A. develops and markets in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers CHROMID RANGE, a chromogen culture media; RAPIDEC CARBA NP biochemical test for the detection of carbapenemaseproducing bacteria; air, surface, and water monitoring systems; BACT/ALERT VIRTUO BACT/ALERT 3D, a blood sample culture system; BIOFIRE, a multiplex polymerase chain reaction (PCR) system; BIOFIRE SPOTFIRE Lowplex PCR point-of-care system; VITEK MS, a mass spectrometry system; VITEK 2, an automated Identification and antimicrobial susceptibility testing (AST) system; API RANGE standardized ID strips; VITEK REVEAL Rapid AST system; ETEST Gradient method on culture media; BIOMERIEUX EPISEQ CS whole genome sequencing solution for epidemiologic monitoring; and VIDASB·R·A·H·M·S PCTTM, a specific marker of severe bacterial infections/sepsis. It also provides Biomérieux vision suite, a software that provides actionable information to support diagnosis and clinical decision making; culture media and associated instruments; ARGENE Monoplex PCR tests; NUCLISENS ranges, a product for automation of the molecular biology laboratory and extraction; EMAG system For DNA and RNA extraction; ESTREAM, an automated preparation station for samples to process PCR tests; GENE-UP and VERIFLOW ranges for detection of microorganisms for the food industry. The company serves clinical and hospital laboratories, physicians, blood banks, vets, and industrial control laboratories. bioMérieux S.A. was formerly known as B-D Mérieux. The company was founded in 1963 and is headquartered in Marcy-l'Étoile, France. bioMérieux S.A. is a subsidiary of Institut Mérieux SA.
www.biomerieux.com14,147
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: BMXXY
View MorePerformance Overview: BMXXY
Trailing total returns as of 6/9/2025, which may include dividends or other distributions. Benchmark is CAC 40 (^FCHI) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: BMXXY
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BMXXY
View MoreValuation Measures
Market Cap
16.48B
Enterprise Value
16.52B
Trailing P/E
31.15
Forward P/E
24.57
PEG Ratio (5yr expected)
1.48
Price/Sales (ttm)
3.38
Price/Book (mrq)
3.18
Enterprise Value/Revenue
3.63
Enterprise Value/EBITDA
16.08
Financial Highlights
Profitability and Income Statement
Profit Margin
10.86%
Return on Assets (ttm)
7.23%
Return on Equity (ttm)
10.68%
Revenue (ttm)
3.98B
Net Income Avi to Common (ttm)
432.2M
Diluted EPS (ttm)
0.42
Balance Sheet and Cash Flow
Total Cash (mrq)
449.8M
Total Debt/Equity (mrq)
11.65%
Levered Free Cash Flow (ttm)
297.79M